Acura Pharma faces mid-October 2026 funding deadline

Q: How much did ACUR borrow from Abuse Deterrent Pharma?

Acura received a $100,000 loan on September 18, 2026, and another $100,000 loan on October 2, 2026. The company said the funding was used for day-to-day operations, and both loans were added to its secured promissory note.

Q: What is ACUR's principal balance and accrued interest under the note?

The note had a principal balance of $11,294,279 and approximately $1,365,000 in accrued interest as of September 30, 2026. It bears interest at 5.25%.

Q: What happens if ACUR misses a payment under the note?

An amount unpaid when due bears interest at 7.5% per year from the date of nonpayment until paid in full. Events of default also include failure to pay principal or interest that continues for five days, bankruptcy events, and specified inability-to-pay-debts conditions.

Acura Pharmaceuticals received a $100,000 loan from Abuse Deterrent Pharma, LLC on each of September 18 and October 2, 2026.

Filing Impact

(High)

Filing Sentiment

(Very Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Acura Pharmaceuticals received a $100,000 loan from Abuse Deterrent Pharma, LLC on each of September 18 and October 2, 2026. The loans were added to its secured promissory note, which had a principal balance of $11,294,279 and approximately $1,365,000 in accrued interest as of September 30, 2026; the note bears interest at 5.25%. Acura said the funding was used for day-to-day operations.

Overdue amounts bear interest at 7.5% per year from nonpayment until paid. Events of default include bankruptcy events, failure to pay principal or interest that continues for five days, and Acura generally not being able to pay its debts as they become due, being unable to do so, or admitting in writing its inability to do so. Acura said that without additional financing by mid-October 2026, it will be required to scale back operations, including furloughing or laying off employees, or terminate operations and/or seek bankruptcy protection; this could result in a complete loss of shareholder value. Acura also identified December 31, 2026 as the date by which it is required to pay off the note and accrued interest.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance works How Sentiment works

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

None.

Negative

Major point. Forward-looking: it has not happened yet and may not happen.Mid-October 2026 funding deadline could lead to cuts, layoffs or bankruptcy.

Filing Explained

Separately from the note’s repayment deadline, Acura says its agreement with Abuse Deterrent Pharma requires FDA acceptance of an NDA for LTX-03 by December 31, 2026; the filing says the deadline may need renegotiation and that Acura depends on the lender to finance operations.

8-K Event Classification

4 items: 1.01, 2.01, 2.03, 9.01

4 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.01 Completion of Acquisition or Disposition of Assets Financial

The company completed a significant acquisition or sale of business assets.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Loan amount: $100,000 per loan Principal balance: $11,294,279 Accrued interest: Approximately $1,365,000 +4 more

7 metrics

Loan amount $100,000 per loan One loan received on each of September 18, 2026 and October 2, 2026

Principal balance $11,294,279 Secured promissory note balance

Accrued interest Approximately $1,365,000 As of September 30, 2026

Interest rate 5.25% Rate on the note

Overdue amount interest rate 7.5% per year Applies from nonpayment until the overdue amount is paid in full

Additional financing deadline Mid-October 2026 Acura said it would be required to scale back operations or take other stated actions without additional financing by this time

Note and accrued interest payoff date December 31, 2026 Date Acura said it is required to pay off the secured promissory note and accrued interest

Key Terms

secured promissory note, accrued interest, Events of default, New Drug Application

4 terms

secured promissory note financial

"Amended Consolidated and Restated Secured Promissory Note"

A secured promissory note is a written promise to repay borrowed money that is backed by specific assets pledged as collateral; if the borrower fails to pay, the lender can seize those assets to recover losses. Investors care because the collateral reduces the lender’s risk and can make the loan safer and more likely to be repaid, similar to a pawnshop loan where an item lowers the lender’s exposure if the borrower defaults.

accrued interest financial

"with accrued interest of approximately $1,365,000"

Accrued interest is the amount of interest that has built up on a loan, bond, or similar investment since the last payment date but has not yet been paid. For investors this matters because when you buy or sell a fixed‑income security between payment dates you compensate the other party for that earned interest—think of it like buying a house mid‑month and reimbursing the seller for days of heating already used—so it affects the actual cash you pay, the yield you receive, and short‑term returns.

Events of default financial

"Events of default under the Note include"

Events of default are specific breaches or failures listed in a loan, bond, or credit agreement that give lenders the right to act, such as demanding immediate repayment, raising interest rates, or taking secured assets. They matter to investors because triggering one is like setting off a financial alarm: it raises the chance of foreclosure, restructuring, or bankruptcy and can sharply reduce the value of a company’s stock or bonds and increase borrowing costs.

New Drug Application regulatory

"submit a New Drug Application for LTX-03"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did ACUR borrow from Abuse Deterrent Pharma?

Acura received a $100,000 loan on September 18, 2026, and another $100,000 loan on October 2, 2026. The company said the funding was used for day-to-day operations, and both loans were added to its secured promissory note.

What is ACUR's principal balance and accrued interest under the note?

The note had a principal balance of $11,294,279 and approximately $1,365,000 in accrued interest as of September 30, 2026. It bears interest at 5.25%.

What happens if ACUR misses a payment under the note?

An amount unpaid when due bears interest at 7.5% per year from the date of nonpayment until paid in full. Events of default also include failure to pay principal or interest that continues for five days, bankruptcy events, and specified inability-to-pay-debts conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/06/2026 - 04:16 PM Accepted by SEC EDGAR 10/06/2026 - 04:16 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported): October 2, 2026

ACURA PHARMACEUTICALS, INC.

(Exact Name of Registrant as specified in its Charter)

New York	1-10113	11-0853640
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)

616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip code)

(847) 705-7709

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, $0.01 par value per share	ACUR	OTC Market – OTC Expert Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01 - Entry into a Material Definitive Agreement.

On each of September 18, 2026 and October 2, 2026, we received a $100,000 loan from Abuse Deterrent Pharma, LLC (“AD Pharma”). This loan combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now has a principal balance of $11,294,279 with accrued interest of approximately $1,365,000 as of September 30, 2026 and bears interest at 5.25% (“Note”). The Events of default under the Note include, among other items, bankruptcy events, failure to pay interest and principal when due and such failure continues for 5 days, and if Acura is generally not, or is unable to, or admits in writing its inability to, pay its debts as those debts become due. If any amount payable hereunder is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration, or otherwise, including upon an event of default, such overdue amount shall bear interest at the rate per annum of 7.5% from the date of such non-payment until such amount is paid in full.

The funding provided by AD Pharma was used to meet day-to-day operation activity. There can be no assurance we will be successful in receiving additional financing. In the absence of the receipt of additional financing by mid-October 2026, we will be required to scale back our operations, including the furlough and lay-off of employees, or to terminate operations and/or seek protection under applicable bankruptcy laws. This could result in a complete loss of shareholder value in the Company. Even assuming we are successful in securing additional sources of financing to fund continued operations, there can be no assurance that the proceeds of such financing will be sufficient to fund operations until such time, if at all, that we generate sufficient revenue from our products and product candidates to sustain and grow our operation.

The inclusion of a description of the Note under Item 1.01 of this Current Report on Form 8-K shall not be deemed an acknowledgement that the Note is a material agreement not made, or deemed not to be made, in the ordinary course of our business.

Item 2.01 – Completion of Acquisition or Disposition of Assets

The contents of all Items 1.01 are incorporated herein by reference.

Item 2.03 - Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The contents of all Items 1.01 are incorporated herein by reference.

Acura Forward-Looking Statements

Statements in this Current Report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and these forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.

Forward-looking statements may include, but are not limited to:

	●	whether the FDA will agree with or accept the results of our studies for our product candidates;
	●	the ability to fulfill the FDA requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the laboratory and clinical studies completed to date, the results of laboratory and clinical studies we may complete in the future to support FDA approval of our product candidates and the sufficiency of our development process to meet over-the-counter (“OTC”) Monograph standards, as applicable;
	●	whether we can successfully submit a New Drug Application for LTX-03, request a priority review and whether such filings and requests will be accepted by the FDA;
	●	our ability to obtain funding from Abuse Deterrent Pharma, LLC or other parties for our continuing operations, including the development of our products utilizing our LIMITx™ and Impede® technologies;
	●	whether we can renegotiate the date by which we are required to obtain FDA acceptance, currently December 31, 2026, for an NDA for LTX-03 by our agreement with Abuse Deterrent Pharma, LLC on which we depend to finance operations;
	●	whether we can renegotiate the date by which we are required to pay off the secured promissory note and accrued interest to Abuse Deterrent Pharma, LLC, currently December 31, 2026;
	●	whether our licensing partners will develop any additional products and utilize Acura for such development;
	●	the expected results of clinical studies relating to LTX-03, a LIMITx hydrocodone bitartrate and acetaminophen combination product, or any successor product candidate, the date by which such studies will be complete and the results will be available and whether LTX-03 will ultimately receive FDA approval;
	●	our business could be adversely affected by health epidemics in regions where third parties for which we rely, as in CROs or CMOs, have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of third-party manufacturers and CROs upon whom we rely;

	●	whether LIMITx will retard the release of opioid active ingredients as dose levels increase;
	●	whether the extent to which products formulated with the LIMITx Technology reduce respiratory depression will be determined sufficient by the FDA to support approval or labelling describing safety features;
	●	our and our licensee’s ability to successfully launch and commercialize our products and technologies;
	●	the results and timing of our development of our LIMITx Technology, including, but not limited to, the submission of a NDA and/or FDA filing acceptance;
	●	our or our licensees’ ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies;
	●	the market acceptance of, timing of commercial launch and competitive environment for any of our products;
	●	expectations regarding potential market share for our products;
	●	our ability to develop and enter into additional license agreements for our product candidates using our technologies;
	●	our exposure to product liability and other lawsuits in connection with the commercialization of our products;
	●	the increasing cost of insurance and the availability of product liability insurance coverage;
	●	the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties;
	●	the ability of our patents to protect our products from generic competition and our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation;
	●	the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support FDA approval of our product candidates;
	●	changes in regulatory requirements;
	●	adverse safety findings relating to our commercialized products or product candidates in development;
	●	whether the FDA will agree with our analysis of our clinical and laboratory studies;
	●	whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and whether we will be able to promote the features of our technologies; and
	●	whether our product candidates will ultimately perform as intended in commercial settings.

In some cases, you can identify forward-looking statements by terms such as “aim”, "anticipate", "believe", "could", "design", "estimate", "expect", "forecast", "goal", "guidance", "imply", “indicate”, "intend", "may", "objective", "opportunity", "outlook", "plan", "position", "potential", "predict", "project", "prospective", "pursue", "seek", "should", "strategy", "target", "would", "will", and other words of similar meaning, expressions, derivations of such words and the use of future dates intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in Acura’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission ("SEC") and in other filings Acura makes with the SEC from time to time. Investors and potential investors are urged not to place undue reliance on forward-looking statements in this communication, which speak only as of this date of the Current Report and are based on the Company’s current beliefs, assumptions, and expectations. While Acura may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking statements contained in this Current Report whether as a result of new information or future events, except as may be required by applicable law.

Item 9.01 - Financial Statements and Exhibits

Exhibit Number	Description
99.1	Amended Loan Schedule dated October 6, 2026 to the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note with Abuse Deterrent Pharma, LLC
104	Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ACURA PHARMACEUTICALS, INC.

	By:	/s/ Robert A. Seiser
		Robert A. Seiser
		Senior Vice President & Chief Financial Officer

Date:

October 6, 2026

Exhibit 99.1

Amended Loan Schedule to Secured Promissory Note dated November 10, 2022

between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC

	Date	Principal		Aggregated Principal
Original Secured Promissory Note	11/10/2022	$	2,319,279	$	2,319,279
Additional Loans to be included:
Loans #1 dated 12/22/2022 through Loans #50 dated 12/31/2025		$	7,075,000	$	9,394,279
Loan #51	1/02/2026	$	100,000	$	9,494,279
Loan #52	1/16/2026	$	100,000	$	9,594,279
Loan #53	2/06/2026	$	100,000	$	9,694,279
Loan #54	2/13/2026	$	100,000	$	9,794,279
Loan #55	3/09/2026	$	100,000	$	9,894,279
Loan #56	3/30/2026	$	100,000	$	9,994,279
Loan #57	4/03/2026	$	100,000	$	10,094,279
Loan #58	4/20/2026	$	100,000	$	10,194,279
Loan #59	5/05/2026	$	100,000	$	10,294,279
Loan #60	5/15/2026	$	100,000	$	10,394,279
Loan #61	5/29/2026	$	100,000	$	10,494,279
Loan #62	6/24/2026	$	200,000	$	10,694,279
Loan #63	7/17/2026	$	200,000	$	10,894,279
Loan #64	8/14/2026	$	200,000	$	11,094,279
Loan #65	9/18/2026	$	100,000	$	11,194,279
Loan #66	10/02/2026	$	100,000	$	11,294,279

ACURA PHARMACEUTICALS, INC.

By:

/s/ Robert A. Seiser

Robert A. Seiser

Senior Vice President & CFO

Date: October 6, 2026

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

EX-99.1 EXHIBIT 99.1 16.7 KB